Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
Children's Allegra Hives is an oral, orally disintegrating tablet formulation of fexofenadine hydrochloride, a selective peripheral H1-receptor antagonist indicated for allergic conditions in pediatric populations. The drug works by blocking histamine receptors to reduce itching, hives, and other allergic symptoms without significant central nervous system penetration.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team consolidation and shift toward lifecycle extension or transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition
Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions
Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
Worked on CHILDREN'S ALLEGRA HIVES at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job openings and approaching LOE, career opportunities on Children's Allegra Hives are limited and declining. Positions tied to this asset are primarily focused on commercial wind-down, generic transition management, and maximizing remaining exclusivity period rather than growth or innovation.